Table S1 Quality assessment.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First author's name** | **Trial name** | **Random sequence generation** | **Allocation concealment** | **Blinding of participants and personnel for all outcomes** | **Blinding of outcome assessors for all outcomes** | **Incomplete outcome data for all outcomes** | **Selective outcome reporting** | **Other bias** |
| Reck et al | AVAiL | low | low | low | low | low | low | low |
| Zhou et al | Beyond | low | low | low | low | low | low | low |
| Zhou et al | CameL | low | unclear | low | low | low | low | low |
| Sandler et al | ECOG4599 | low | unclear | low | low | low | low | low |
| Galetta et al | ERACLE | low | low | low | unclear | low | low | low |
| West et al | IMpower130 | low | low | high | high | low | low | low |
| Barlesi et al | IMpower132 | low | unclear | high | high | low | low | low |
| Socinski et al | IMpower150 | low | low | high | high | low | low | low |
| Nishio et al | JO19907 | low | unclear | high | high | low | low | low |
| Corey et al | KeyNote 021 | low | low | high | low | low | low | low |
| Gadgeel et al | KeyNote 189 | low | low | low | low | low | low | low |
| Yang et al | ORIENT-11 | low | low | low | low | low | low | low |
| Ralph et al | PRONOUNCE | low | unclear | high | high | low | low | low |
| Sugawara et al | TASUKI-52 | low | unclear | low | low | low | low | low |
| Lu et al | RATIONALE 304 | low | low | high | high | unclear | unclear | low |
| Paz-Ares et al | CheckMate 227 | low | low | high | high | low | low | low |

Table S2 Sensitivity analysis for bevacizumab plus chemotherapy versus chemotherapy for PFS in overall population.

|  |  |  |  |
| --- | --- | --- | --- |
| Study omitted | HR | 95% CI Lower | 95% CI Upper |
| AVAiL | 0.67 | 0.50 | 0.91 |
| Beyond | 0.79 | 0.65 | 0.96 |
| ECOG4599 | 0.71 | 0.52 | 0.98 |
| ERACLE | 0.69 | 0.53 | 0.91 |
| JO19907 | 0.72 | 0.55 | 0.95 |
| PRONOUNCE | 0.65 | 0.51 | 0.83 |

†PFS, progression free survival; HR, hazard ratio; CI, confidence interval.

Table S3 Sensitivity analysis for bevacizumab plus chemotherapy versus chemotherapy for ORR in overall population.

|  |  |  |  |
| --- | --- | --- | --- |
| Study omitted | OR | 95% CI Lower | 95% CI Upper |
| AVAiL | 2.10 | 1.17 | 3.78 |
| Beyond | 1.84 | 1.10 | 3.06 |
| ECOG4599 | 1.85 | 1.10 | 3.11 |
| ERACLE | 2.16 | 1.30 | 3.58 |
| JO19907 | 1.86 | 1.12 | 3.06 |
| PRONOUNCE | 2.46 | 1.75 | 3.46 |

†ORR, objective response rate; OR, odds ratio; CI, confidence interval.

Table S4 Sensitivity analysis for anti-PD-L1 plus chemotherapy versus chemotherapy for PFS in PD-L1 negative population.

|  |  |  |  |
| --- | --- | --- | --- |
| Study omitted | HR | 95% CI Lower | 95% CI Upper |
| IMpower130 | 0.45 | 0.31 | 0.65 |
| Impower132 | 0.72 | 0.56 | 0.92 |

†PFS, progression free survival; HR, hazard ratio; CI, confidence interval.